Latent Tuberculosis Infection Detected by Quantiferon-TB Assay in Patients with Multiple Myeloma Receiving Novel Drugs: Focus on Reactivation Prophylaxis in a Retrospective, Single-center Study
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Anibarro L, Pena A
. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014026.
PMC: 4010605.
DOI: 10.4084/MJHID.2014.026.
View
2.
Getahun H, Matteelli A, Abubakar I, Abdel Aziz M, Baddeley A, Barreira D
. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015; 46(6):1563-76.
PMC: 4664608.
DOI: 10.1183/13993003.01245-2015.
View
3.
Gitman M, Vu J, Nguyen T, Chen C, Rotstein C
. Evaluation of a routine screening program with tuberculin skin testing on rates of detection of latent tuberculosis infection and prevention of active tuberculosis in patients with multiple myeloma at a Canadian cancer centre. Curr Oncol. 2020; 27(3):e246-e250.
PMC: 7339840.
DOI: 10.3747/co.27.5577.
View
4.
Tsai C, Huon L, Ou S, Kuan A, Yeh C, Lee Y
. Risk and impact of tuberculosis in patients with multiple myeloma. Leuk Lymphoma. 2017; 58(11):2598-2606.
DOI: 10.1080/10428194.2017.1312369.
View
5.
Ahn J, Rew S, Yang D, Jung S, Kang S, Kim M
. Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Res. 2013; 48(1):35-9.
PMC: 3625000.
DOI: 10.5045/br.2013.48.1.35.
View